Journal Club #5: The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Bipolar Depression.
Article: Harv Rev Psychiatry. 2010 Jan-Feb;18(1):36-55.
This journal club will compare the following two guidelines for bipolar depression management:
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines.
- Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Bipolar Depression (2019)
These guidelines will be compared in terms of First, Second and Third line treatment.
This journal club will answer the following ten clinically relevant questions:
- Which medications are not recommended treatment for bipolar depression?
- Which Non-FDA approved medication is the first line treatment per both guidelines?
- Which FDA approved treatment is not recommended by Harvard South Shore program update?
- “Adjunctive” use of which medication is considered first line treatment per CANMAT & ISBD guidelines?
- Which one medication moved from second line treatment (in CANMAT & ISBD) to first line treatment (in Harvard South Shore program update)?
- “Monotherapy” with which medication is considered third-line treatment per CANMAT & ISBD guideline?
- Which medication(s) was recommended by CANMAT but NOT recommended by Harvard South Shore program update due to safety concerns?
- Which antidepressant is preferred as an adjunctive treatment, over other antidepressants?
- Do aripiprazole have efficacy as monotherapy or as an adjunct or no efficacy for bipolar depression?
- Which non-medication option was recommended by both guidelines?
PSYCHIATRY EDUCATION FORUM’S
JOURNAL CLUB SCHEDULE:
(1) ISNPR Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.
- Psychother Psychosom. 2019;88(5):263-273.
- Release Date: May 09, 2020.
(2) Almost all Antipsychotics Result in Weight Gain: Meta-Analysis.
- PLoS One. 2014 Apr 24;9(4):e94112.
- Release Date: May 16, 2020.
(3) Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study.
- Int J Neuropsychopharmacol. 2019 Nov 1;22(11):681-697.
- Release Date: May 23, 2020.
(4) Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
- JAMA Psychiatry. 2020 Jan 8.
- Release Date: May 30, 2020.
(5) The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Bipolar Depression.
- Harv Rev Psychiatry. 2010 Jan-Feb;18(1):36-55.
- Release Date: June 06, 2020.
(6) Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
- N Engl J Med. 2020 Apr 16;382(16):1497-1506.
- Release Date: June 13, 2020.
TOTAL 1.50 AMA PRA CATEGORY 1 CME CREDITS AVAILABLE FOR FIRST SIX JOURNAL CLUB LECTURES.
CME Credits™ Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute, LLC and Psychiatry Education Forum LLC. The PeerPoint Medical Education Institute, LLC is accredited by the ACCME to provide continuing medical education for physicians. The PeerPoint Medical Education Institute, LLC designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.